An optimized cyclophosphamide-treated mouse model of Mycobacterium abscessus pulmonary infection

Cited 0 times in

Authors: Yan Sun ; Kaixi Zhang ; May Delos Santos ; Carmen J E Pee ; Yanmeng Yang ; Meiqi Kang ; Sung Jae Shin ; Mary B Chan-Park ; Kevin Pethe

Citation: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Vol.68(8) : e0152023, 2024-08

MeSH: Amikacin* / pharmacology ; Amikacin* / therapeutic use ; Animals ; Anti-Bacterial Agents* / pharmacology ; Anti-Bacterial Agents* / therapeutic use ; Cyclophosphamide* / pharmacology ; Disease Models, Animal* ; Female ; Imipenem / pharmacology ; Imipenem / therapeutic use ; Immunocompromised Host ; Lung / drug effects ; Lung / microbiology ; Mice ; Mycobacterium Infections, Nontuberculous* / drug therapy ; Mycobacterium Infections, Nontuberculous* / microbiology ; Mycobacterium abscessus* / drug effects

Abstract: Mycobacterium abscessus pulmonary infections are increasingly problematic, especially for immunocompromised individuals and those with underlying lung conditions. Currently, there is no reliable standardized treatment, underscoring the need for improved preclinical drug testing. We present a simplified immunosuppressed mouse model using only four injections of cyclophosphamide, which allows for sustained M. abscessus lung burden for up to 16 days. This model proved effective for antibiotic efficacy evaluation, as demonstrated with imipenem or amikacin.